Substance Use and Survival after Treatment for Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS)

Author： Chang Grace Meadows Mary-Ellen Jones Jennifer A. Antin Joseph H. Orav E. John

ISSN： 0095-2990

Source： The American Journal of Drug and Alcohol Abuse, Vol.36, Iss.1, 2010-01, pp. : 1-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Agents in the Treatment of Chronic Myelogenous Leukemia

By Pinilla-Ibarz Javier Quintás-Cardama Alfonso

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 9, 2009-10 ,pp. : 1028-1037

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia

Current Cancer Drug Targets, Vol. 13, Iss. 1, 2013-01 ,pp. : 69-79

Bentham Science Publishers

Access to resources Recommend Favorite

Chronic Myelogenous Leukemia Guidelines

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 5, 2007-05 ,pp. : 474-474

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

New Agents in Chronic Myelogenous Leukemia

By Cortes Jorge Giles Francis

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 501-512

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

By Issa Jean-Pierre Garcia-Manero Guillermo Huang Xuelin Cortes Jorge Ravandi Farhad Jabbour Elias Borthakur Gautam Brandt Mark Pierce Sherry Kantarjian Hagop M.

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 556-561

Blackwell Publishing

Access to resources Recommend Favorite